Preventing in-hospital cardiac and renal complications in high-risk PCI patients

European Heart Journal, Supplement

Volumn 7, Issue G, 2005, Pages

  Brinker, Jeffrey A ^a   Davidson, Charles J ^b   Laskey, Warren ^c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

CIN; Contrast media; Contrast induced nephropathy; MACE; Major adverse cardiac events; Osmolality; Renal insufficiency; Risk assessment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CONTRAST MEDIUM; FIBRINOGEN RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE;

AGE DISTRIBUTION; ALGORITHM; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; DEATH; DIABETES MELLITUS; HEART DISEASE; HEART EJECTION FRACTION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYDRATION; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; NEPHROTOXICITY; OSMOLARITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; UNSTABLE ANGINA PECTORIS; VASCULAR ACCESS;

EID: 31944436967     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui054     Document Type: Review

References (65)

1. Dzavik V. New frontiers and unresolved controversies in percutaneous coronary intervention. Am J Cardiol 2003;91:27A-33A.
2. American Heart Association. Heart disease and stroke statistics: 2004 update. www.americanheart.org (12 August 2004)
3. Smith SC Jr, Dove JT, Jacobs AK et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001;103:3019-3041.
4. Bavry AA, Kumbhani DJ, Quiroz R et al. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. Am J Cardiol 2004;93:830-835.
5. Henderson RA, Pocock SJ, Clayton TC et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003;42:1161-1170.
6. Heuser R, Houser F, Culler SD et al. A retrospective study of 6,671 patients comparing coronary stenting and balloon angioplasty. J Invasive Cardiol 2000;12:354-362.
7. Diegeler A, Thiele H, Falk V et al. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. N Engl J Med 2002;347:561-566.
8. Watanabe CT, Maynard C, Ritchie JL. Short-term outcomes after percutaneous coronary intervention: effects of stenting and institutional volume shifts. Am Heart J 2002;144:310-314.
9. Williams DO, Holubkov R, Yeh W et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation 2000;102:2945-2951.
10. Bartholomew BA, Harjai KJ, Dukkipati S et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:1515-1519.
11. Block PC, Peterson ED, Krone R et al. Identification of variables needed to risk adjust outcomes of coronary interventions: evidence-based guidelines for efficient data collection. J Am Coll Cardiol 1998;32:275-282.
12. Laskey WK, Kimmel S, Krone RJ. Contemporary trends in coronary intervention: a report from the Registry of the Society for Cardiac Angiography and Interventions. Catheter Cardiovasc Interv 2000;49:19-22.
13. Kimmel SE, Localio AR, Krone RJ et al. The effects of contemporary use of coronary stents on in-hospital mortality. Registry Committee of the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 2001;37:499-504.
14. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
15. Anderson HV, Shaw RE, Brindis RG et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol 2002;39:1096-1103.
16. Keelan PC, Johnston JM, Koru-Sengul T et al. Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions ≤40%, 41% to 49%, and ≥50% having percutaneous coronary revascularization. Am J Cardiol 2003;91:1168-1172.
17. Morcos SK. Prevention of contrast media nephrotoxicity - the story so far. Clin Radiol 2004;59:381-389.
18. Aspelin P, Aubry P, Fransson SG et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-499.
19. Alamartine E, Phayphet M, Thibaudin D et al. Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations. Eur J Intern Med 2003;14:426-431.
20. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
21. McCullough PA, Wolyn R, Rocher LL et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
22. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
23. Ellis SG, Weintraub W, Holmes D et al. Relation of operator volume and experience to procedural outcome of percutaneous coronary revascularization at hospitals with high interventional volumes. Circulation 1997;95:2479-2484.
24. Moscucci M, Kline-Rogers E, Share D et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation 2001;104:263-268.
25. Hannan EL, Racz M, Ryan TJ et al. Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. JAMA 1997;277:892-898.
26. O'Connor GT, Malenka DJ, Quinton H et al. Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994-1996. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 1999;34:681-691.
27. Qureshi MA, Safian RD, Grines CL et al. Simplified scoring system for predicting mortality after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1890-1895.
28. Shaw RE, Anderson HV, Brindis RG et al. Updated risk adjustment mortality model using the complete 1.1 dataset from the American College of Cardiology National Cardiovascular Data Registry (ACC-NCDR). J Invasive Cardiol 2003;15:578-580.
29. Kizer JR, Berlin JA, Laskey WK et al. Limitations of current risk-adjustment models in the era of coronary stenting. Am Heart J 2003;145:683-692.
30. Kimmel SE, Berlin JA, Strom BL et al. Development and validation of simplified predictive index for major complications in contemporary percutaneous transluminal coronary angioplasty practice. The Registry Committee of the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1995;26:931-938.
31. Singh M, Rihal CS, Selzer F et al. Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2003;42:1722-1728.
32. Lindsay J, Apple S, Pinnow EE et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:338-343.
33. Mehran R, Aymong ED, Nikolsky E et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-1399.
34. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-2131.
35. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998;98:1802-1820.
36. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998;352:87-92.
37. Freeman RV, Mehta RH, Al Badr W et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003;41:718-724.
38. Steinhubl SR, Ellis SG, Wolski K et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001;103: 1403-1409.
39. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-533.
40. Steinhubl SR, Berger PB, Mann JT III et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420.
41. Stone GW, Ellis SG, Cox DA et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-1947.
42. Chew DP, Bhatt DL, Kimball W et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003;92:919-923.
43. Almen T. The etiology of contrast medium reactions. Invest Radiol 1994;29(Suppl. 1):S37-S45.
44. Corot C, Chronos N, Sabattier V. In vitro comparison of the effects of contrast media on coagulation and platelet activation. Blood Coagul Fibrinolysis 1996;7:602-608.
45. Heptinstall S, White A, Edwards N et al. Differential effects of three radiographic contrast media on platelet aggregation and degranulation: implications for clinical practice? Br J Haematol 1998;103:1023-1030.
46. Bertrand ME, Esplugas E, Piessens J et al. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty VIP Trial Investigators. Circulation 2000;101:131-136.
47. Davidson CJ, Laskey WK, Hermiller JB et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000;101:2172-2177.
48. Harrison J, Hermiller J, Vetrovec G et al. A randomized study of 1276 patients undergoing PCI using iodixanol (Visipaque) vs iopamidol (Isovue): Comparison of in-hospital and 30-day major adverse cardiac events. The results of the VICC Trial. Circulation 2003;108:IV-354.
49. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 2003;181:1463-1471.
50. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol 1999;9:1602-1613.
51. Taliercio CP, Vlietstra RE, Fisher LD et al. Risks for renal dysfunction with cardiac angiography. Ann Intern Med 1986;104:501-504.
52. Freeman RV, O'Donnell M, Share D et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002;90:1068-1073.
53. Jakobsen JA, Berg KJ, Kjaersgaard P et al. Angiography with nonionic X-ray contrast media in severe chronic renal failure: renal function and contrast retention. Nephron 1996;73:549-556.
54. Mueller C, Buerkle G, Buettner HJ et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-336.
55. Solomon R, Werner C, Mann D et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.
56. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol 1981;136:859-861.
57. Taylor AJ, Hotchkiss D, Morse RW et al. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998;114:1570-1574.
58. Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-2334.
59. Birck R, Krzossok S, Markowetz F et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598-603.
60. Pannu N, Manns B, Lee H et al. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004;65:1366-1374.
61. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999;72:701-703.
62. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998;352:87-92.
63. Almen T. Visipaque - a step forward. A historical review. Acta Radiol Suppl 1995;399:2-18.
64. Iomeprol - a promising new nonionic contrast medium. Drug Ther Perspect 2001;17:1-4.
65. Sovak M, Terry R, Abramjuk C et al. Iosimenol, a low-viscosity nonionic dimer: preclinical physicochemistry, pharmacology, and pharmacokinetics. Invest Radiol 2004;39:171-181.